Investigating a peptide to promote remyelination in multiple sclerosis
Official title: Remyelination by intranasal TIDM peptide
Funded at Jesse Brown VA Medical Center · NIH-11101303 · Data updated 2026-11-12
This study is exploring a new treatment for people with multiple sclerosis that uses a special nasal spray to help repair the protective covering of nerve fibers, with the hope of improving nerve function and easing symptoms.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jesse Brown VA Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX005613-03 |
| Project ID | NIH-11101303 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple sclerosis, particularly those experiencing symptoms related to nerve damage.
✕Less likely to help
Patients with other neurological disorders or those who do not have multiple sclerosis may not benefit from this research.
What this research studies
This research focuses on finding new ways to promote remyelination in patients with multiple sclerosis (MS), a condition where the protective covering of nerve fibers is damaged. The approach involves using an intranasal peptide that targets specific immune pathways to enhance the repair of myelin in the central nervous system. By understanding how this peptide interacts with immune cells, the research aims to develop a novel treatment that could restore nerve function and improve symptoms for those affected by MS.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that helps repair nerve damage in multiple sclerosis, potentially improving quality of life for patients.
How similar studies have gone: While there have been various approaches to treating multiple sclerosis, the specific use of intranasal peptides for remyelination is a novel and untested strategy.
Where this research is happening
-
Jesse Brown VA Medical Center
Chicago, United States Active
Researchers
- Principal investigator: Pahan, Kalipada — Jesse Brown VA Medical Center
- Study coordinator: Pahan, Kalipada
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.